You’ve been told your blood pressure is ‘normal’ — and left the clinic feeling reassured. But a wave of clinical trial evidence, capped by sweeping 2025 guideline changes, suggests the number your doctor is targeting may be 10 to 20 points higher than what the research now supports. If you have a family history of heart disease and you’re banking on standard reassurance, this is the study breakdown you need to read.
The frustration is a familiar one. You do the right things — you show up for your annual check, you report your readings, you hear that your numbers are acceptable — and you leave feeling like you’ve done your due diligence. But ‘acceptable’ and ‘optimal’ are not the same word. For people carrying a family history of cardiovascular disease, that gap between the two may be the most important health distinction you’re not being told about.
What the Research Actually Says About Blood Pressure Targets
The number your guidelines are built on — and why it keeps shifting
Blood pressure guidelines have not always looked the way they do today. The threshold that defined hypertension — the point at which elevated pressure in your arteries (what we call hypertension) required treatment — has been revised repeatedly as clinical evidence accumulates. The 2025 AHA/ACC hypertension guidelines represent the most recent major update to these targets, incorporating findings from decades of clinical trials and risk data drawn from lifetime registry cohorts. The direction of travel has consistently been the same: lower.
This matters because a large portion of adults currently classified as ‘normal’ or ‘elevated’ under previous standards now fall into a different risk category under the updated framework. The target hasn’t shifted because scientists are being cautious. It’s shifted because the data from long-running trials made the old number increasingly difficult to defend.
What SPRINT found, what it proved, and where critics say it overshoots
The most influential trial in this space is the SPRINT study — a large, NIH-funded randomised trial that compared two groups: one targeting a systolic pressure (the top number in a blood pressure reading) below 140 mmHg, and one targeting below 120 mmHg. The group with the lower target had significantly fewer cardiovascular events. The trial was stopped early because the benefit was considered so clear it would have been unethical to continue denying the intensive group’s result to the control group.
Powerful. But not uncontested. A Cochrane systematic review assessing whether SPRINT should directly change clinical practice concluded that the evidence requires careful interpretation before wholesale adoption. Critics within medical communities have pointed to the unblinded design, the method by which blood pressure was measured in SPRINT (automated and unattended, producing numbers systematically lower than typical clinical readings), and the narrow demographic studied. The headline finding was real. The question of how cleanly it translates to your specific situation is a different and harder question.
The Core Finding Translated: What Does ‘Intensive Control’ Actually Mean?
Below 120 vs. below 140 — the cardiovascular risk gap explained in plain English
Think of your blood pressure target like a speed limit set for an entire highway system. The national limit is designed for average conditions — dry roads, daylight, mixed traffic. But if you’re driving a heavy truck in the wet, or you’re 70 years old with older brakes, the right speed for you may be different from what the sign says. The research is now telling us that the standard blood pressure speed limit was set for average risk — and if your family history puts you in a higher-risk vehicle, you may need a different number on your personal sign.
Lowering blood pressure targets has been associated with reduced risk of cardiovascular problems including heart attack, stroke, heart failure, and cardiovascular death across multiple lines of trial evidence. The mechanism is not complicated in principle: sustained pressure against artery walls accelerates the process of plaque quietly building inside those walls (what researchers call atherosclerosis), reduces the elasticity of vessels, and increases the mechanical strain on the heart muscle. Lower pressure, consistently maintained, reduces all of these downstream effects. The disagreement is not about whether lower is better in principle. It’s about how low, for whom, and at what cost.
Why the Lancet benefit-harm analysis changes the conversation for people over 60
A Lancet analysis comparing intensive blood pressure targets — below 120 mmHg or below 130 mmHg — against standard treatment found that the benefit-harm trade-off shifts based on patient profile. This is the sentence that most general health coverage skips past. The composite benefit — fewer heart attacks, fewer strokes, less heart failure — is real. But it is not evenly distributed. Age, baseline kidney function, medication burden, and existing cardiovascular disease all affect whether pushing a target aggressively delivers net benefit or introduces new risk. For someone in their forties with elevated systolic pressure and a family history of early heart disease, intensive control is likely the right conversation to be having. For someone in their late sixties managing multiple conditions on several medications, the calculus is genuinely different.
The Nuance the Headlines Miss
When lower is not always better — the older adult paradox
Here is the counterintuitive finding that tends to get buried: low blood pressure has been linked to increased mortality in seniors, with international experts noting that guidelines moving toward tight blood pressure targets may not be appropriate for all older adults. The biological reason is not mysterious. In older adults, the circulation to the brain, kidneys, and heart depends on a minimum level of pressure to perfuse adequately. Push that number too low — especially with medication — and you risk falls, fainting, kidney function decline, and reduced oxygen delivery to organs that are already working harder to compensate for ageing. The risk of over-treating is real, and it gets more real with every decade.
Blood pressure variability: why one reading at the clinic tells only half the story
There is a dimension to this conversation that even motivated health optimisers often underestimate. The single reading your doctor records — taken once, often after a walk from the waiting room, occasionally in the context of mild anxiety about being at a clinic — is a snapshot of a dynamic system. Blood pressure variability is now emerging as an independent predictor of cardiovascular risk, meaning that the fluctuation in your readings over time may carry as much predictive weight as the average level itself. Someone whose pressure swings significantly between morning and evening, or between resting and activity, may be carrying a risk profile that a single clinic number simply cannot capture. Home monitoring over multiple days and times of day is increasingly what the evidence supports — not because clinic readings are useless, but because they are incomplete.
Why people with existing heart disease may not benefit from the same aggressive targets
You might assume that if you already have established cardiovascular disease, you’d be the prime candidate for the most aggressive blood pressure target available. The evidence does not straightforwardly support that assumption. Current evidence is insufficient to justify lower blood pressure targets of 135/85 mmHg or below in people with hypertension and established cardiovascular disease — a finding from a Cochrane-based evidence review that sits in direct tension with the instinct to do more for those already diagnosed. It reflects a pattern seen repeatedly in medicine: the populations most likely to be offered aggressive intervention are sometimes the ones in whom the evidence for it is weakest, partly because clinical trial populations used to set blood pressure targets frequently exclude specific subgroups, meaning the targets derived from those trials may not fully apply to populations with different risk profiles or comorbidities.
What This Means for You — If You Have a Family History
The difference between population-level targets and your personal risk threshold
Population-level guidelines exist because they work at scale. They reduce cardiovascular mortality across millions of people. They are not designed to answer the question you are actually asking, which is: given my family history, my age, my other risk factors, and my specific numbers — what target is right for me? Those are different questions with different answers, and conflating them is precisely how motivated, health-aware adults end up leaving a routine appointment with false reassurance.
The challenge is that this is exactly the kind of question a routine annual check-up was not designed to answer — not because your doctor doesn’t care, but because population-level reference ranges were never built to account for your specific risk profile. A GP working within a standard appointment slot, using standard reference ranges, is answering a population question. You are asking a personal one. A systematic review of randomised controlled trials on optimal antihypertensive systolic blood pressure targets in adults reflects the ongoing scientific effort to define the right number across different patient populations — which is another way of saying the field itself has not arrived at a single universal answer. Your situation deserves the same rigour.
One biomarker question to take to your next appointment
At your next blood pressure check, ask for your last three readings — not just today’s number. If your average systolic sits between 120 and 139, ask your doctor: ‘Given my family history, is my current target based on standard population guidelines or on my personal cardiovascular risk profile?’ That single question opens the conversation the research says most patients never have.
